


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Starsportned

STAR SPORTS MEDICINE CO., LTD.

北京天星醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01609)

**PROPOSED ABOLITION OF THE BOARD OF SUPERVISORS
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND
RULES OF PROCEDURE AND
2025 PROFIT DISTRIBUTION PLAN**

PROPOSED ABOLITION OF THE BOARD OF SUPERVISORS

The board (the “**Board**”) of directors (the “**Directors**”) of Star Sports Medicine Co., Ltd. (the “**Company**”) is pleased to announce that, in accordance with the latest regulatory requirements under the Company Law of the People’s Republic of China (《中華人民共和國公司法》), the Guidelines for the Articles of Association of Listed Companies (《上市公司章程指引》) and the Rules of Shareholders’ Meetings of Listed Companies (《上市公司股東會規則》) issued by the China Securities Regulatory Commission, as well as other applicable laws and regulations – which require listed companies in the PRC to abolish their board of supervisors and further improve corporate governance – the Company proposes to abolish its Board of Supervisors, and the relevant powers and functions of the Board of Supervisors will be exercised by the Audit Committee of the Board.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURE

To reflect the aforementioned proposed abolition of the Board of Supervisors and comply with relevant laws and regulations and corporate governance requirements, the Company intends to make corresponding amendments to the Articles of Association of Star Sports Medicine Co., Ltd. (《北京天星醫療股份有限公司章程》), and amend accordingly the Rules of Procedure for the Board of Directors of Star Sports Medicine Co., Ltd. (《北京天星醫療股份有限公司董事會議事規則》) and the Rules of Procedure for the Shareholders’ Meeting of Star Sports Medicine Co., Ltd. (《北京天星醫療股份有限公司股東會議事規則》).

The proposed abolition of the Board of Supervisors and proposed amendments to the Articles of Association and Rules of Procedure set out above are subject to approval by the Shareholders by way of special resolution at the 2025 annual shareholders' meeting of the Company. From the date on which the revised Articles of Association become effective, the current Supervisors of the Company shall be relieved of their duties, and the Rules of Procedure for the Board of Supervisors shall be abolished accordingly. Until the Shareholders of the Company approve the amendments to the Articles of Association at the 2025 annual shareholders' meeting of the Company, the Board of Supervisors will continue to exercise its powers and functions with due diligence to safeguard the interests of the Company and all Shareholders. A circular containing, among other things, details of the resolutions on the proposed abolition of the Board of Supervisors and proposed amendments to the Articles of Association and Rules of Procedure, as well as the notice of the annual shareholders' meeting, will be published on the websites of HKEXnews (<https://www.hkexnews.hk>) and the Company (<https://www.star-sportsmed.com>), and will be despatched to Shareholders (if applicable) in accordance with the requirements of the Listing Rules in due course.

2025 PROFIT DISTRIBUTION PLAN

The Board hereby announces that it does not recommend the payment of any dividend for the year ended December 31, 2025.

By order of the Board
Star Sports Medicine Co., Ltd.
Mr. Dong Wenxing
Chairman of the Board and Executive Director

Hong Kong, June 5, 2026

As at the date of this announcement, the Board comprises Mr. Dong Wenxing and Mr. He Lu as executive Directors; Ms. Zhang Di, Mr. Chang Xi, Mr. David Guowei Wang, Ms. Yi Lin and Mr. Zhou Quan as non-executive Directors; and Mr. Lyu Zhenlin, Mr. Deng Yu, Mr. Liu Baojie and Mr. Wang Chunfei as independent non-executive Directors.